Recent Developments in Cancer Systems Biology
This ebook includes original research articles and reviews to update readers on the state of the art systems approach to not only discover novel diagnostic and prognostic biomarkers for several cancer types, but also evaluate methodologies to map out important genomic signatures. In addition, therap...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_76720 | ||
| 005 | 20220111 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20220111s2021 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-1471-0 | ||
| 020 | |a 9783036514727 | ||
| 020 | |a 9783036514710 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-1471-0 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a Sinha, Raghu |4 edt | |
| 700 | 1 | |a Arga, Kazim Yalcin |4 edt | |
| 700 | 1 | |a Sinha, Raghu |4 oth | |
| 700 | 1 | |a Arga, Kazim Yalcin |4 oth | |
| 245 | 1 | 0 | |a Recent Developments in Cancer Systems Biology |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
| 300 | |a 1 electronic resource (272 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This ebook includes original research articles and reviews to update readers on the state of the art systems approach to not only discover novel diagnostic and prognostic biomarkers for several cancer types, but also evaluate methodologies to map out important genomic signatures. In addition, therapeutic targets and drug repurposing have been emphasized for a variety of cancer types. In particular, new and established researchers who desire to learn about cancer systems biology and why it is possibly the leading front to a personalized medicine approach will enjoy reading this book. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a Sestrin2 | ||
| 653 | |a lung cancer | ||
| 653 | |a knockdown | ||
| 653 | |a cancer progression | ||
| 653 | |a bioinformatics | ||
| 653 | |a patient survival | ||
| 653 | |a lung adenocarcinoma | ||
| 653 | |a circulating miR-1246 | ||
| 653 | |a glycosaminoglycan binding | ||
| 653 | |a prognosis | ||
| 653 | |a PI3K-Akt signaling pathways | ||
| 653 | |a TargetScan | ||
| 653 | |a UBE2C | ||
| 653 | |a cancer systems biology | ||
| 653 | |a experimental model systems | ||
| 653 | |a next-generation sequencing | ||
| 653 | |a single-cell sequencing | ||
| 653 | |a patient-derived xenografts | ||
| 653 | |a patient-derived organoids | ||
| 653 | |a triple-negative breast cancer | ||
| 653 | |a personalized medicine | ||
| 653 | |a computational methods | ||
| 653 | |a drug repurposing | ||
| 653 | |a clinical trials | ||
| 653 | |a cancer stem cells | ||
| 653 | |a ETS | ||
| 653 | |a Elk-1 | ||
| 653 | |a stem cell | ||
| 653 | |a microarray | ||
| 653 | |a brain-tumor-initiating cell (BTIC) | ||
| 653 | |a pancreatic cancer | ||
| 653 | |a systems biology | ||
| 653 | |a omics | ||
| 653 | |a biomarker | ||
| 653 | |a genomics | ||
| 653 | |a transcriptomics | ||
| 653 | |a proteomics | ||
| 653 | |a metabolomics | ||
| 653 | |a glycomics | ||
| 653 | |a metagenomics | ||
| 653 | |a Ets | ||
| 653 | |a PEA3 | ||
| 653 | |a Ets-1 | ||
| 653 | |a glioma | ||
| 653 | |a optical genome mapping | ||
| 653 | |a solid tumors | ||
| 653 | |a cancer genomics | ||
| 653 | |a breast | ||
| 653 | |a ovarian | ||
| 653 | |a cancer | ||
| 653 | |a TCGA | ||
| 653 | |a non-small-cell lung cancer | ||
| 653 | |a lung adenocarcinoma (LUAD) | ||
| 653 | |a lung squamous cell carcinoma (LUSC) | ||
| 653 | |a differential expression | ||
| 653 | |a SNV | ||
| 653 | |a CNV | ||
| 653 | |a risk group | ||
| 653 | |a signature | ||
| 653 | |a survival | ||
| 653 | |a renal cancers | ||
| 653 | |a protein interactome | ||
| 653 | |a diagnostic biomarker | ||
| 653 | |a prognostic biomarker | ||
| 653 | |a virtual screening | ||
| 653 | |a docking | ||
| 653 | |a acute myeloid leukemia | ||
| 653 | |a Boolean model | ||
| 653 | |a drug resistance | ||
| 653 | |a network | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/4169 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/76720 |7 0 |z DOAB: description of the publication |